Subject
Spectroscopy,Instrumentation,Atomic and Molecular Physics, and Optics,Analytical Chemistry
Reference23 articles.
1. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase;Huang;J. Med. Chem.,2016
2. U.S. FDA., FDA approves Brigatinib for the treatment of patients with metastatic (ALK)-positive (NSCLC), 2017.
3. Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation;Hatcher;J. Med. Chem.,2015
4. Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry;Darwish;Clin. Chim. Acta,2018
5. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates;Sparidans;J. Pharm. Biomed. Anal.,2018